Home World News Significant OS Benefit with Glofitamab plus GemOx in Transplant-Ineligible Patients with Relapsed... World News Significant OS Benefit with Glofitamab plus GemOx in Transplant-Ineligible Patients with Relapsed or Refractory DLBCL By Ogkologos - December 6, 2024 920 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the STARGLO study Source RELATED ARTICLESMORE FROM AUTHOR Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR Implanted “Drug Factories” Deliver Cancer Treatment Directly to Tumors April 7, 2022 EMA Adopts Positive Opinion for Pemetrexed Baxter November 3, 2022 FDA Approves Nivolumab for Resected Oesophageal or Gastro-oesophageal Junction Cancer May 25, 2021 Bladder Cancer Trial Finds Extended Lymph Node Surgery Doesn’t Improve Survival November 6, 2024 Load more HOT NEWS EMA Recommends Granting a Marketing Authorisation for Quizartinib Change Your Thoughts, Change Your World Building a Support Community During Cancer: “Your Stories” Podcast 5-Year-Old Boy Surprised With Paycheck For Helping Electrical Company Fix His...
